Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study

Dawei Yang, Xiaoju Zhang, Charles A. Powell, Jun Ni, Bin Wang, Jianya Zhang, Yafei Zhang, Lijie Wang, Zhihong Xu, Li Zhang, Guoming Wu, Yong Song, Wenhua Tian, Jia An Hu, Yong Zhang, Jie Hu, Qunying Hong, Yuanlin Song, Jian Zhou, Chunxue Bai

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

BACKGROUND: The authors built a model for lung cancer diagnosis previously based on the blood biomarkers progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and cytokeratin 19 fragment (CYFRA21-1). In the current study, they examined whether modification of the model to include relevant clinical information, risk factors, and low-dose chest computed tomography screening would improve the performance of the biomarker panel in large cohorts of Chinese adults. METHODS: The current study was a large-scale multicenter study (ClinicalTrials.gov identifier NCT01928836) performed in a Chinese population. A total of 715 participants were enrolled from 5 regional centers in Beijing, Henan, Nanjing, Shanghai, and Chongqing between October 2012 and February 2014. Serum biomarkers ProGRP, CEA, SCC, and CYFRA21-1 were analyzed on the ARCHITECT i2000SR. Relevant clinical information was collected and used to develop a patient risk model and a nodule risk model. RESULTS: The resulting patient risk model had an area under the receiver operating characteristic (ROC) curve of 0.7037 in the training data set and 0.7190 in the validation data set. The resulting nodule risk model had an area under the ROC curve of 0.9151 in the training data set and 0.5836 in the validation data set. Moreover, the nodule risk model had a relatively higher area under the ROC curve (0.9151 vs 0.8360; P = 0.001) compared with the American College of Chest Physician model in patients with lung nodules. CONCLUSIONS: Both the patient risk model and the nodule risk model, developed for the early diagnosis of lung cancer, demonstrated excellent discrimination, allowing for the stratification of patients with different levels of lung cancer risk. These new models are applicable in high-risk Chinese populations. Cancer 2018;124:262-70.

Original languageEnglish
Pages (from-to)262-270
Number of pages9
JournalCancer
Volume124
Issue number2
DOIs
StatePublished - 15 Jan 2018

Keywords

  • Chinese population
  • biomarker
  • cancer diagnosis
  • cancer risk
  • lung cancer

Fingerprint

Dive into the research topics of 'Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study'. Together they form a unique fingerprint.

Cite this